



## **Kuwait**



#### **Category Scores**



### **Overall Score in Comparison**





# Kuwait



## Key Areas of Strength

- The administrative IP enforcement option is available and in use through the National Library and Ministry of Commerce and Industry; led to the disabling of access to thousands of websites offering counterfeit and IP-infringing goods
- Basic IP framework is in place
- Participant in regional patent and trademark harmonization efforts through GCC

### Key Areas of Weakness

- No special IP incentives for orphan medicinal product development
- Uncertainty about the future of the GCC
   patent and how/whether the regional
   patenting route will continue to exist
- Most sector-specific rights are missing
- Barriers are in place for licensing and technology transfer
- No R&D or IP-specific tax incentives are in place
- No targeted incentives for the creation and use of IP assets for SMEs
- Limited participant in international treaties

Indicator	Score
Category 1: Patents Rights and Limitations	3.00
1. Term of protection	1.00
2. Patentability requirements	0.50
3. Patentability of CIIs	0.25
4. Plant variety protection	0.00
5. Pharmaceutical-related enforcement	0.00
<ol><li>Legislative criteria and use of compulsory licensing</li></ol>	1.00
7. Pharmaceutical patent term restoration	0.00
8. Membership of a Patent Prosecution Highway	0.00
9. Patent opposition	0.25
Category 2: Copyrights and Limitations	3.28
10. Term of protection	0.53
11. Exclusive rights	0.50
<ol> <li>Expeditious legal remedies disabling access to infringing content online</li> </ol>	0.75
13. Cooperative action against online piracy	0.00
14. Limitations and exceptions	0.50
15. TPM and DRM	0.50
16. Government use of licensed software	0.50
Category 3: Trademarks Rights and Limitations	2.50
17. Term of protection	1.00
18. Protection of well-known marks	0.50
19. Exclusive rights, trademarks	0.50
20. Frameworks against online sale of counterfeit goods	0.50
Category 4: Design Rights and Limitations	0.85
21. Industrial design term of protection	0.60
22. Exclusive rights, industrial design rights	0.25
Category 5: Trade Secrets and the Protection of Confidential Information	0.50
23. Protection of trade secrets (civil remedies)	0.25
24. Protection of trade secrets (criminal sanctions)	0.25
25. Regulatory data protection term	0.00
Category 6: Commercialization of IP Assets	2.00
26. Barriers to market access	0.00
27. Barriers to technology transfer	0.50
28. Registration and disclosure requirements of licensing deals	0.50
· · · · · · · · · · · · · · · · · · ·	

Indicator	Score
29. Direct government intervention	
in setting licensing terms	0.50
30. IP as an economic asset	0.50
31. Tax incentives for the creation of IP assets	0.00
Category 7: Enforcement	2.34
32. Physical counterfeiting rates	0.41
33. Software piracy rates	0.43
34. Civil and precedural remedies	0.25
35. Pre-established damages	0.25
36. Criminal standards	0.25
37. Effective border measures	0.50
38. Transparency and public reporting by customs	0.25
Category 8: Systemic Efficiency	0.50
39. Coordination of IP rights enforcement	0.00
40. Consultation with stakeholders	
during IP policy formation	0.25
41. Educational campaigns and awareness raising	0.25
42. Targeted incentives for the creation and use of IP assets for SMEs	0.00
43. IP-intensive industries, national economic impact analysis	0.00
coolionne impact analysis	0.00
Category 9: Cutting-Edge Innovation	0.00
Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal	0.00
Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development	
Category 9: Cutting-Edge Innovation         44. IP incentives for orphan medicinal product development         45. IP incentives for orphan medicinal product development, term of protection	0.00
<ul> <li>Category 9: Cutting-Edge Innovation</li> <li>44. IP incentives for orphan medicinal product development</li> <li>45. IP incentives for orphan medicinal product development, term of protection</li> <li>46. Restrictions on the effective use of existing IP incentives for orphan</li> </ul>	0.00 0.00 0.00
<ul> <li>Category 9: Cutting-Edge Innovation</li> <li>44. IP incentives for orphan medicinal product development</li> <li>45. IP incentives for orphan medicinal product development, term of protection</li> <li>46. Restrictions on the effective use</li> </ul>	<b>0.00</b>
<ul> <li>Category 9: Cutting-Edge Innovation</li> <li>44. IP incentives for orphan medicinal product development</li> <li>45. IP incentives for orphan medicinal product development, term of protection</li> <li>46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development</li> <li>Category 10: Membership and Ratification</li> </ul>	0.00 0.00 0.00
<ul> <li>Category 9: Cutting-Edge Innovation</li> <li>44. IP incentives for orphan medicinal product development</li> <li>45. IP incentives for orphan medicinal product development, term of protection</li> <li>46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development</li> </ul>	0.00 0.00 0.00
Category 9: Cutting-Edge Innovation         44. IP incentives for orphan medicinal product development         45. IP incentives for orphan medicinal product development, term of protection         46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development         Category 10: Membership and Ratification of International Treaties         47. WIPO Internet Treaties	0.00 0.00 0.00
Category 9: Cutting-Edge Innovation         44. IP incentives for orphan medicinal product development         45. IP incentives for orphan medicinal product development, term of protection         46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development         Category 10: Membership and Ratification of International Treaties	0.00 0.00 0.00 0.00
<ul> <li>Category 9: Cutting-Edge Innovation</li> <li>44. IP incentives for orphan medicinal product development</li> <li>45. IP incentives for orphan medicinal product development, term of protection</li> <li>46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development</li> <li>Category 10: Membership and Ratification of International Treaties</li> <li>47. WIPO Internet Treaties</li> <li>48. Singapore Treaty on the Law of Trademarks and Protocol Relating to the Madrid Agreement</li> </ul>	0.00 0.00 0.00 0.00 0.50 0.00
<ul> <li>Category 9: Cutting-Edge Innovation</li> <li>44. IP incentives for orphan medicinal product development</li> <li>45. IP incentives for orphan medicinal product development, term of protection</li> <li>46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development</li> <li>Category 10: Membership and Ratification of International Treaties</li> <li>47. WIPO Internet Treaties</li> <li>48. Singapore Treaty on the Law of Trademarks and Protocol Relating to the Madrid Agreement Concerning the International Registration of Marks</li> </ul>	0.00 0.00 0.00 0.00 0.00
<ul> <li>Category 9: Cutting-Edge Innovation</li> <li>44. IP incentives for orphan medicinal product development</li> <li>45. IP incentives for orphan medicinal product development, term of protection</li> <li>46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development</li> <li>Category 10: Membership and Ratification of International Treaties</li> <li>47. WIPO Internet Treaties</li> <li>48. Singapore Treaty on the Law of Trademarks and Protocol Relating to the Madrid Agreement Concerning the International Registration of Marks</li> <li>49. Patent Law Treaty and Patent Cooperation Treaty</li> <li>50. Membership of the International Convention for the Protection of New Varieties of Plants, act of 1991</li> <li>51. Membership of the Convention</li> </ul>	0.00 0.00 0.00 0.00 0.00 0.00 0.50
<ul> <li>Category 9: Cutting-Edge Innovation</li> <li>44. IP incentives for orphan medicinal product development</li> <li>45. IP incentives for orphan medicinal product development, term of protection</li> <li>46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development</li> <li>Category 10: Membership and Ratification of International Treaties</li> <li>47. WIPO Internet Treaties</li> <li>48. Singapore Treaty on the Law of Trademarks and Protocol Relating to the Madrid Agreement Concerning the International Registration of Marks</li> <li>49. Patent Law Treaty and Patent Cooperation Treaty</li> <li>50. Membership of the International Convention for the Protection of New Varieties of Plants, act of 1991</li> <li>51. Membership of the Convention on Cybercrime, 2001</li> <li>52. The Hague Agreement Concerning the</li> </ul>	0.00 0.00 0.00 0.00 0.00 0.50 0.00 0.00
<ul> <li>Category 9: Cutting-Edge Innovation</li> <li>44. IP incentives for orphan medicinal product development</li> <li>45. IP incentives for orphan medicinal product development, term of protection</li> <li>46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development</li> <li>Category 10: Membership and Ratification of International Treaties</li> <li>47. WIPO Internet Treaties</li> <li>48. Singapore Treaty on the Law of Trademarks and Protocol Relating to the Madrid Agreement Concerning the International Registration of Marks</li> <li>49. Patent Law Treaty and Patent Cooperation Treaty</li> <li>50. Membership of the International Convention for the Protection of New Varieties of Plants, act of 1991</li> <li>51. Membership of the Convention on Cybercrime, 2001</li> </ul>	0.00 0.00 0.00 0.00 0.00 0.00 0.50

Percentage of Overall Score: 29.19%

Total Score: 15.47

•

## Spotlight on the National IP Environment

#### Past Editions versus Current Score

Kuwait's overall Index score has increased from 14.21 out of 50 indicators in the twelfth edition to 15.47 out of 53 indicators. This reflects a score increase for indicators 11, 12, 18, 19, and 20.

#### Copyrights and Limitations; and Trademark Rights and Limitations

11. Legal measures, which provide necessary exclusive rights that prevent infringement of copyrights and related rights (including web hosting, streaming, and linking); 12. Expeditious disabling of infringing content online; 18. Protection of well-known marks; 19. Legal measures available that provide necessary exclusive rights to redress unauthorized uses of trademarks; and 20. Availability of frameworks that promote action against online sale of counterfeit goods: The IP enforcement environment in Kuwait has long been difficult. Although civil remedies, including injunctive relief, the suspension of alleged infringing activities, and the seizure of infringing materials and goods are available for most major IP rights, active enforcement has been lacking.

In a positive development, over the past few years, some notable improvements have been made to Kuwait's national IP environment and, in particular, the enforcement of IP rights online. As noted in the Index at the time, in 2019, Law 75 on Copyright and Related Rights, was enacted. This made some important changes to Kuwait's copyright regime with potential new avenues for copyright enforcement. Specifically, Article 36 grants a broader type of administrative enforcement authority to designated officials compared with the provisions in the older Copyright Law. Kuwait's National Library administers the national system of copyright and has, since the coming into force of these amendments, offered rightsholders the option of filing copyright infringement complaints directly through an online portal. This administrative enforcement option comes on top of a pre-existing mechanism run by the Communications and Information Technology Authority (CITRA).

Since 2014–2015, laws related to telecommunications and cybercrime have invested vast powers in CITRA to oversee and regulate the online space. These laws have also included some reference to the protection of IP rights. For example, under Law No. 37 of 2014 on the "Establishment of Communication and Information Technology Regulatory Authority," CITRA has the power to suspend operating licenses and individual accounts. CITRA offers a dedicated web portal where online requests for the disabling of websites can be requested, including for IP infringement. In late 2022, these powers of administrative enforcement were extended to other IP rights, including trademarks.

Like the National Library, today the Ministry of Commerce and Industry offers rightsholders the ability to submit infringement complaints directly through its website. As of 2024 rightsholders can directly lodge complaints and request the disabling of access to any online access point offering access to IP infringing content and/or goods electronically directly via several Government of Kuwait websites. As a result, public reporting suggests that the government disabled thousands of online access points over the past few years. Significantly, many of these access points were disabled based on IP infringement. As a result of these continued positive efforts, the scores for indicators 11, 12, 18, 19, and 20 have increased.

#### **Incentives for Cutting-Edge Innovation**

44. Special market exclusivity incentives for orphan medicinal product development; 45. Special market exclusivity incentives for orphan medicinal product development, term of protection; and 46. Restrictions on the effective use of existing market exclusivity incentives for orphan medicinal product development:

Interest in rare diseases has grown in the Middle East and North Africa region. In 2003, the Centre for Arab Genomic Studies was established to map and improve the state of care for patients with genetic diseases in the Arab world. Today, the Center has become the leading research point for rare diseases in the region. Several Index economies in the region, including Saudi Arabia and the UAE, have introduced a defined regulatory sanitary registration pathway and special incentives for orphan products. Since 1979, the Kuwait Medical Genetic Centre has provided genetic screening services and patient care. In 2018, the Ministry of Health introduced fast-track sanitary registration of orphan products. The Ministry of Health also runs a national newborn screening program. Kuwait does not have in place any special IP-based market exclusivity incentives for orphan medicinal product development.